Cytek Biosciences (CTKB)
(Real Time Quote from BATS)
$5.38 USD
+0.27 (5.28%)
Updated Sep 17, 2024 11:10 AM ET
3-Hold of 5 3
C Value B Growth A Momentum B VGM
Balance Sheet
Fiscal Year End for Cytek Biosciences, Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 263 | 344 | 365 | 166 | -99,999 |
Receivables | 56 | 49 | 30 | 17 | NA |
Notes Receivable | 0 | 0 | 0 | 0 | NA |
Inventories | 61 | 48 | 32 | 23 | NA |
Other Current Assets | 13 | 13 | 5 | 3 | NA |
Total Current Assets | 392 | 454 | 432 | 209 | NA |
Net Property & Equipment | 18 | 14 | 6 | 2 | NA |
Investments & Advances | 0 | 0 | 0 | 0 | NA |
Other Non-Current Assets | 0 | 0 | 0 | 0 | NA |
Deferred Charges | 30 | 20 | 9 | 7 | NA |
Intangibles | 39 | 14 | 15 | 1 | NA |
Deposits & Other Assets | 3 | 3 | 2 | 1 | NA |
Total Assets | 494 | 519 | 463 | 220 | NA |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | NA |
Accounts Payable | 3 | 5 | 3 | 3 | NA |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | NA |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | NA |
Accrued Expenses | 20 | 21 | 15 | 9 | NA |
Income Taxes Payable | 0 | 0 | 0 | 0 | NA |
Other Current Liabilities | 33 | 23 | 15 | 15 | NA |
Total Current Liabilities | 56 | 49 | 33 | 27 | NA |
Mortgages | 0 | 0 | 0 | 0 | NA |
Deferred Taxes/Income | 15 | 13 | 10 | 3 | NA |
Convertible Debt | 0 | 0 | 0 | 0 | NA |
Long-Term Debt | 2 | 2 | 0 | 0 | NA |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | NA |
Other Non-Current Liabilities | 19 | 17 | 15 | 12 | NA |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | NA |
Total Liabilities | 101 | 94 | 58 | 42 | NA |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 194 | NA |
Common Stock (Par) | 0 | 0 | 0 | 0 | NA |
Capital Surplus | 423 | 443 | 424 | 6 | NA |
Retained Earnings | -29 | -17 | -20 | -23 | NA |
Other Equity | -1 | 0 | 1 | 0 | NA |
Treasury Stock | 0 | 0 | 0 | 0 | NA |
Total Shareholder's Equity | 393 | 426 | 405 | 178 | NA |
Total Liabilities & Shareholder's Equity | 494 | 519 | 463 | 220 | NA |
Total Common Equity | 393 | 426 | 405 | -16 | 0 |
Shares Outstanding | 135.50 | 134.80 | 133.70 | NA | NA |
Book Value Per Share | 2.90 | 3.16 | 3.03 | 0.00 | 0.00 |
Fiscal Year End for Cytek Biosciences, Inc falls in the month of December.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 277 | 270 | 263 | 288 | 299 |
Receivables | 45 | 50 | 56 | 55 | 50 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 50 | 55 | 61 | 67 | 66 |
Other Current Assets | 12 | 13 | 13 | 12 | 11 |
Total Current Assets | 384 | 389 | 392 | 422 | 425 |
Net Property & Equipment | 18 | 18 | 18 | 17 | 16 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 30 | 33 | 30 | 24 | 26 |
Intangibles | 38 | 38 | 39 | 41 | 43 |
Deposits & Other Assets | 5 | 4 | 3 | 3 | 3 |
Total Assets | 484 | 492 | 494 | 519 | 525 |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 3 | 4 | 3 | 5 | 3 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 15 | 18 | 20 | 21 | 20 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 34 | 34 | 33 | 33 | 31 |
Total Current Liabilities | 52 | 56 | 56 | 59 | 54 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 14 | 15 | 15 | 15 | 16 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 1 | 1 | 2 | 2 | 2 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 19 | 19 | 18 | 19 | |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 95 | 99 | 101 | 104 | 101 |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 435 | 429 | 423 | 452 | 454 |
Retained Earnings | -46 | -35 | -29 | -35 | -28 |
Other Equity | 0 | -2 | -1 | -2 | -2 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 389 | 393 | 393 | 416 | 424 |
Total Liabilities & Shareholder's Equity | 484 | 492 | 494 | 519 | 525 |
Total Common Equity | 389 | 393 | 393 | 416 | 424 |
Shares Outstanding | 131.20 | 131.20 | 135.50 | 136.30 | 135.60 |
Book Value Per Share | 2.97 | 2.99 | 2.90 | 3.05 | 3.13 |